1. Home
  2. SNT vs BOLD Comparison

SNT vs BOLD Comparison

Compare SNT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$1.75

Market Cap

64.6M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.47

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
BOLD
Founded
1965
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
57.5M
IPO Year
2023
2024

Fundamental Metrics

Financial Performance
Metric
SNT
BOLD
Price
$1.75
$2.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
29.2K
2.4M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.96
52 Week High
$5.34
$2.79

Technical Indicators

Market Signals
Indicator
SNT
BOLD
Relative Strength Index (RSI) 23.69 68.79
Support Level $1.71 $1.07
Resistance Level $2.87 $2.79
Average True Range (ATR) 0.14 0.12
MACD 0.01 -0.03
Stochastic Oscillator 9.21 31.08

Price Performance

Historical Comparison
SNT
BOLD

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: